FDA seeks public input on ibogaine trial design

FDA Requests Public Feedback on Ibogaine Trials

The U.S. Food and Drug Administration (FDA) is calling for public input on the design of early-phase clinical trials for ibogaine, a psychoactive compound under investigation for treating opioid use disorder and PTSD. This request for information (RFI) seeks comments on key trial components such as dose selection, safety monitoring, and ethical oversight, with submissions due by November 20, 2026, according to Applied Clinical Trials Online.

What the Request Covers

The FDA's RFI outlines several areas for public comment, including the selection of appropriate patient populations, dose escalation strategies, and safety protocols to monitor potential cardiac and neurological side effects. The agency is particularly interested in ensuring that the starting dose does not exceed 10 mg/kg. Ethical considerations, such as informed consent and independent safety oversight, are also highlighted as critical components.

Regulatory Context

This initiative is part of a broader governmental effort to accelerate research into psychedelic medicines, following an executive order signed by President Trump in April 2026. The order directed the Department of Health and Human Services (HHS) to prioritize research on psychedelic therapies for serious mental illnesses. The FDA's actions align with this directive, as they have issued national priority vouchers for companies studying similar compounds like psilocybin and methylone.

Why It Matters

The FDA's focus on ibogaine trials underscores the growing interest in psychedelic treatments for mental health conditions that are resistant to existing therapies. With opioid use disorder and PTSD being significant public health challenges, the potential for ibogaine to offer new treatment options is noteworthy. The agency's emphasis on rigorous scientific investigation aims to ensure that any new therapies are both effective and safe.

The FDA's move to solicit public input is a step toward developing a robust regulatory framework for emerging psychedelic therapies, reflecting a shift in how these substances are perceived within the medical community.